These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 29146922)

  • 1. Molecular definition of multiple sites of antibody inhibition of malaria transmission-blocking vaccine antigen Pfs25.
    Scally SW; McLeod B; Bosch A; Miura K; Liang Q; Carroll S; Reponen S; Nguyen N; Giladi E; Rämisch S; Yusibov V; Bradley A; Lemiale F; Schief WR; Emerling D; Kellam P; King CR; Julien JP
    Nat Commun; 2017 Nov; 8(1):1568. PubMed ID: 29146922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nasal immunization with a malaria transmission-blocking vaccine candidate, Pfs25, induces complete protective immunity in mice against field isolates of Plasmodium falciparum.
    Arakawa T; Komesu A; Otsuki H; Sattabongkot J; Udomsangpetch R; Matsumoto Y; Tsuji N; Wu Y; Torii M; Tsuboi T
    Infect Immun; 2005 Nov; 73(11):7375-80. PubMed ID: 16239536
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New adenovirus-based vaccine vectors targeting Pfs25 elicit antibodies that inhibit Plasmodium falciparum transmission.
    McGuire KA; Miura K; Wiethoff CM; Williamson KC
    Malar J; 2017 Jun; 16(1):254. PubMed ID: 28619071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25.
    Mlambo G; Maciel J; Kumar N
    Infect Immun; 2008 May; 76(5):2018-24. PubMed ID: 18316385
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent antibody lineage against malaria transmission elicited by human vaccination with Pfs25.
    McLeod B; Miura K; Scally SW; Bosch A; Nguyen N; Shin H; Kim D; Volkmuth W; Rämisch S; Chichester JA; Streatfield S; Woods C; Schief WR; Emerling D; King CR; Julien JP
    Nat Commun; 2019 Sep; 10(1):4328. PubMed ID: 31551421
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Induction of Plasmodium falciparum transmission-blocking antibodies in nonhuman primates by a combination of DNA and protein immunizations.
    Coban C; Philipp MT; Purcell JE; Keister DB; Okulate M; Martin DS; Kumar N
    Infect Immun; 2004 Jan; 72(1):253-9. PubMed ID: 14688103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent malaria transmission-blocking antibody responses elicited by Plasmodium falciparum Pfs25 expressed in Escherichia coli after successful protein refolding.
    Kumar R; Angov E; Kumar N
    Infect Immun; 2014 Apr; 82(4):1453-9. PubMed ID: 24421036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poor CD4
    Zaric M; Marini A; Nielsen CM; Gupta G; Mekhaiel D; Pham TP; Elias SC; Taylor IJ; de Graaf H; Payne RO; Li Y; Silk SE; Williams C; Hill AVS; Long CA; Miura K; Biswas S
    Front Immunol; 2021; 12():732667. PubMed ID: 34659219
    [No Abstract]   [Full Text] [Related]  

  • 9. Transmission-blocking activity induced by malaria vaccine candidates Pfs25/Pvs25 is a direct and predictable function of antibody titer.
    Miura K; Keister DB; Muratova OV; Sattabongkot J; Long CA; Saul A
    Malar J; 2007 Aug; 6():107. PubMed ID: 17686163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Malaria Derived Glycosylphosphatidylinositol Anchor Enhances Anti-Pfs25 Functional Antibodies That Block Malaria Transmission.
    Kapoor N; Vanjak I; Rozzelle J; Berges A; Chan W; Yin G; Tran C; Sato AK; Steiner AR; Pham TP; Birkett AJ; Long CA; Fairman J; Miura K
    Biochemistry; 2018 Feb; 57(5):516-519. PubMed ID: 29323879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and Immunogenicity of Pfs25-EPA/Alhydrogel®, a Transmission Blocking Vaccine against Plasmodium falciparum: An Open Label Study in Malaria Naïve Adults.
    Talaat KR; Ellis RD; Hurd J; Hentrich A; Gabriel E; Hynes NA; Rausch KM; Zhu D; Muratova O; Herrera R; Anderson C; Jones D; Aebig J; Brockley S; MacDonald NJ; Wang X; Fay MP; Healy SA; Durbin AP; Narum DL; Wu Y; Duffy PE
    PLoS One; 2016; 11(10):e0163144. PubMed ID: 27749907
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ; Anderson CF; Riteau N; Rausch K; Scaria P; Kelnhofer ER; Howard RF; Sher A; Germain RN; Duffy P
    Sci Rep; 2017 Jan; 7():40312. PubMed ID: 28091576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancing immunogenicity and transmission-blocking activity of malaria vaccines by fusing Pfs25 to IMX313 multimerization technology.
    Li Y; Leneghan DB; Miura K; Nikolaeva D; Brian IJ; Dicks MD; Fyfe AJ; Zakutansky SE; de Cassan S; Long CA; Draper SJ; Hill AV; Hill F; Biswas S
    Sci Rep; 2016 Jan; 6():18848. PubMed ID: 26743316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pfs230 yields higher malaria transmission-blocking vaccine activity than Pfs25 in humans but not mice.
    Healy SA; Anderson C; Swihart BJ; Mwakingwe A; Gabriel EE; Decederfelt H; Hobbs CV; Rausch KM; Zhu D; Muratova O; Herrera R; Scaria PV; MacDonald NJ; Lambert LE; Zaidi I; Coelho CH; Renn JP; Wu Y; Narum DL; Duffy PE
    J Clin Invest; 2021 Apr; 131(7):. PubMed ID: 33561016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel plant-produced Pfs25 fusion subunit vaccine induces long-lasting transmission blocking antibody responses.
    Jones RM; Chichester JA; Manceva S; Gibbs SK; Musiychuk K; Shamloul M; Norikane J; Streatfield SJ; van de Vegte-Bolmer M; Roeffen W; Sauerwein RW; Yusibov V
    Hum Vaccin Immunother; 2015; 11(1):124-32. PubMed ID: 25483525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of CpG oligodeoxynucleotides on the immunogenicity of Pfs25, a Plasmodium falciparum transmission-blocking vaccine antigen.
    Coban C; Ishii KJ; Stowers AW; Keister DB; Klinman DM; Kumar N
    Infect Immun; 2004 Jan; 72(1):584-8. PubMed ID: 14688140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Saccharomyces cerevisiae-secreted fusion proteins Pfs25 and Pfs28 elicit potent Plasmodium falciparum transmission-blocking antibodies in mice.
    Gozar MM; Price VL; Kaslow DC
    Infect Immun; 1998 Jan; 66(1):59-64. PubMed ID: 9423839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural and Immunological Characterization of Recombinant 6-Cysteine Domains of the Plasmodium falciparum Sexual Stage Protein Pfs230.
    MacDonald NJ; Nguyen V; Shimp R; Reiter K; Herrera R; Burkhardt M; Muratova O; Kumar K; Aebig J; Rausch K; Lambert L; Dawson N; Sattabongkot J; Ambroggio X; Duffy PE; Wu Y; Narum DL
    J Biol Chem; 2016 Sep; 291(38):19913-22. PubMed ID: 27432885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthetic peptides from P. falciparum sexual stage 25-kDa protein induce antibodies that react with the native protein: the role of IL-2 and conformational structure on immunogenicity of Pfs25.
    Quakyi IA; Miller LH; Good MF; Ahlers JD; Isaacs SN; Nunberg JH; Houghten RA; Keister DB; Coligan JE; Moss B
    Pept Res; 1995; 8(6):335-44. PubMed ID: 8838417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure and mechanism of a transmission blocking vaccine candidate protein Pfs25 from P. falciparum: a molecular modeling and docking study.
    Sharma B
    In Silico Biol; 2008; 8(3-4):193-206. PubMed ID: 19032156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.